For instance, genetically lowering Arc expression has been shown to ameliorate seizure-like phenotypes in an Angelman syndrome mouse model45, suggesting that achieving the same through neuropharmacology could offer comparable benefits. The gene discussed is ARC; the disease is Angelman syndrome.